MedTrace Logo

Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma

NCT01883518 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2019-11-20

No results posted yet for this study

Summary

The purpose of this study is to achieving a six-month progression free survival (PFS) of patients receiving autologous dendritic cell vaccine (ADKV) loaded with allogeneic tumor lysate expression of cancer-testis antigens (CTA) in patients with soft tissue sarcomas

Conditions

  • Sarcoma
  • Neoplasms, Connective and Soft Tissue

Interventions

BIOLOGICAL

Autologous dendritic cell vaccine

Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens

Sponsors & Collaborators

  • N.N. Petrov National Medical Research Center of Oncology

    lead OTHER

Principal Investigators

  • Yuriy Komarov, PhD · N. N. Petrov Research Institute of oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01883518 on ClinicalTrials.gov